(Alliance News) - GSK PLC on Wednesday reported new test data for its shingles vaccine and for a potential new oral treatment for a form of gonorrhoea.
The Brentford, London-based pharmaceutical company said new long-term data showed its shingles vaccine Shingrix continued to provide high protection against shingles in adults aged 50 and over, 11 years after initial vaccination, with vaccine efficacy standing at 82%.
It noted no new safety concern during the follow-up period.
"Infectious diseases like shingles pose a significant risk to adults due to the natural decline in our immune system, and these data represent a remarkable advancement in our understanding of what can be achieved long-term for effective protection against shingles," said Javier Diez-Domingo, principal investigator at the Foundation for the Promotion of Health & Biomedical Research of the Valencian Community in Spain.
Phil Dormitzer, senior vice president, head of Vaccines research & development at GSK said: "We will continue to evaluate long-term data and conduct real-world evidence studies related to vaccine efficacy, immunogenicity, and safety across indicated populations, including those at highest risk of shingles to assess a potential need for revaccination in future."
Separately, GSK announced that phase 3 trial data showed potential for its antibiotic gepotidacin as a new oral treatment option for uncomplicated urogenital gonorrhoea, a bacterial sexually transmitted infection.
Gepotidacin achieved a near 93% microbiological success rate and was non-inferior to the leading combination treatment, which is intramuscular ceftriaxone plus oral azithromycin.
Chris Corsico, senior vice president at GSK's Development unit, said: "These results highlight the potential of gepotidacin as a new oral treatment option given the rising incidence of gonorrhoea worldwide including drug resistant infections. The imperative for innovative treatments has never been clearer. We are committed to working with health regulators globally to introduce this potential new antibiotic, focusing on solutions that meet critical patient needs."
GSK shares were down 0.8% to 1,597.00 pence each on Wednesday morning in London.
By Tom Budszus, Alliance News slot editor
Comments and questions to newsroom@alliancenews.com
Copyright 2024 Alliance News Ltd. All Rights Reserved.
Glaxosmithkline (GSK)
